You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
醫藥股普遍跑贏 信達生物(01801.HK)漲逾半成
醫藥股今天普遍跑贏大市,尤其是君實生物(01877.HK)旗下VV116產業化項目備案獲張江高科技園區管委會通過,該股終止四連跌,今天重越10天線(43.4元),最高見48元,現報45.2元,急漲12%,成交增至716萬股。 日前獲摩通升價至47元及重申「增持」的信達生物(01801.HK)重越10天線(26.5元),最高見27.25元,現報26.9元,回升5.3%。信達周初公布,用於治療轉移性結直腸癌、轉移性三陰性乳腺癌,晚期非小細胞肺癌,卵巢癌及宮頸癌五項適應症的注射液獲印尼批准使用。 國藥(01099.HK)、神威藥業(02877.HK)、三生製藥(01530.HK)、威高股份(01066.HK)、藥明生物(02269.HK)、中生製藥(01177.HK)及四環醫藥(00460.HK)升逾2%-3%。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account